CD70 and plasma cell myeloma: Preclinical trials have confirmed the high cytotoxic activity of CD70-specific CAR T cells with respect to myeloma cells, whereby the low toxicity of normal tissues has been noted, including hematopoietic stem cells, thanks to minimal CD70 expression of extratumor or activated immune cells [167,168].